The goal of this study is to identify a novel inhibitor with antiinflammatory and antiproliferative properties for the treatment of psoriasis. Compound f152A1 [(3S,5Z,8S,11E)-8,9,16-trihydroxy-14-methoxy-3-methyl-3,4,9,10-tetrahydro-1H-benzo[c][1] oxacyclotetradecine1,7(8H)-dione] was identified as the main active metabolite with strong inhibitory activity against tumor necrosis factor-␣ (TNF␣) transcription in a fraction originated from the fermentation broth of the fungus Curvularia verruculosa. Although active in cell-based assays, f152A1 was unstable in plasma and liver microsome preparations, thus limiting its pharmaceutical utilization. To improve the metabolic properties of f152A1, a medicinal chemistry program was undertaken, resulting in the generation of over 400 analogs of f152A1. Eventually, E6201 [(3S,4R,5Z,8S,9S,11E)-14-(ethylamino)-8, 9,16-trihydroxy-3,4-dimethyl-3,4,9,19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione] was identified as a promising analog in this series. In the present study, we characterized the in vitro activities of E6201 and discovered that the compound inhibits lipopolysaccharide-activated TNF␣ reporter activity in THP-1-33 cells with an IC 50 value of 50 nM and selectively inhibits mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK)-1 and MEK kinase-1 in cell-free biochemical assays. In addition, E6201 showed inhibitory activity in several other cell-based systems: 1) phosphorylation of c-jun N-terminal kinase and p38 MAPKs; 2) nuclear factor-B and activated protein-1 activation in various cell types; 3) interleukin (IL)-2 production from human lymphocytes; 4) hyperproliferation of human keratinocytes; 5) IL-8 production from human keratinocytes; and 6) proinflammatory cytokine production from human peripheral blood mononuclear cells. Based on the data presented here, E6201 may be beneficial for treatment of inflammatory and hyperproliferative diseases such as psoriasis through its anti-inflammatory activities on immune cells and antihyperproliferative activities on keratinocytes.
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ABBREVIATIONS:
TNF␣, tumor necrosis factor-␣; MEK1, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-1; MEKK1, MEK kinase-1; BSA, bovine serum albumin; MAPK, mitogen-activated protein kinase; MKK, MAPK kinase; ERK, extracellular signal-regulated kinase; NF-B, nuclear factor-B; IB␣, inhibitory protein of NF-B; IKK, IB kinase; AP-1, activator protein-1; E6201, (3S,4R,5Z,8S,9S,11E)-14-(ethylamino)-8,9, 16-trihydroxy-3,4-dimethyl-3,4,9,19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione; f152A1, LL-Z1640-2, (3S, 5Z,8S,9S,11E)-8,9,16-trihydroxy-14-methoxy-3-methyl-3,4,9,10-tetrahydro-1H-benzo[c] [1]oxacyclotetradecine-1,7(8H)-dione; f152D2 (hypothemycin), (1aR,3S,4S,9S,15bR,Z)-3,4,12-trihydroxy-14-methoxy-9-methyl-3,4,8,9-tetrahydro-1aH-benzo[c] oxireno [2,3-e] [1]oxacyclotetradecine-5,11(2H,15bH)-dione; f152B1, (3S, 5E,8S,9S,11E)-8,9,16-trihydroxy-14-methoxy-3-methyl-3,4,9,10-tetrahydro-1H-benzo[c] [1]oxacyclotetradecine-1,7(8H)dione; f152C, (E)-8,9,16-trihydroxy-14-methoxy-3-methyl-3,4,5,6,9,10-hexahydro-1H-benzo[c] [1]oxacyclotetradecine-1,7(8H)-dione; (3S, 4R, 5Z, 8S, 9S, 9, 4, 9, [1]oxacyclotetradecine-1,7(8H)-dione; IL, interleukin; EGF, epidermal growth factor; EGFR, EGF receptor; FGFR1, fibroblast growth factor receptor 1; VEGFR2, vascular endothelial growth factor receptor-2; JNK, c-jun N-terminal kinase; MBP, myelin basic protein; PDGFR␤, platelet-derived growth factor receptor-␤; PKC, protein kinase C; TAK1, tissue growth factor ␤-activated kinase-1; FBS, fetal bovine serum; PBMCs, peripheral blood mononuclear cells; PLAP, placental alkaline phosphatase; LPS, lipopolysaccharide; PHA-P, phytohemagglutinin-P; PMA, phorbol 12-myristate 13-acetate; HRP, horseradish peroxidase; GSH, glutathione; GST, glutathione S-transferase; ECL, enhanced chemiluminescence; ELISA, enzyme-linked immunosorbent assay; HTRF, homogeneous time-resolved fluorescence; UTR, untranslated region; 2-ME, 2-mercaptoethanol; THP-1, a human acute monocytic leukemia cell line; Eu (K)-PY20, europium cryptate-conjugated antiphosphotyrosine antibody, PY20; Eu (K)-PT66, europium cryptate-conjugated antiphosphotyrosine antibody, PT66; XL665-SA, streptavidin-conjugated-XL665; Syk, spleen tyrosine kinase; PGK, phosphoglycerine kinase; GA-1000, gentamicin/amphotericin-B; ZAP-70, 70-kDa -associated protein.
Psoriasis, a common inflammatory skin disease characterized by excessive growth and aberrant differentiation of keratinocytes, is estimated to affect approximately 6.4 million patients in the United States (Lebwohl, 2003) . The keratinocyte response in psoriasis is thought to be driven by the activation of the cellular immune system, including T cells, dendritic cells, and various immune-related cytokines. Because major pathogenic abnormalities in patients with psoriasis include hyperproliferation, abnormal differentiation of keratinocytes, and infiltration of inflammatory cells into the skin, compounds that influence these processes may be candidates for the treatment of this disease.
During the course of screening for inhibitors of TNF␣-transcription, f152A1 was found in a fraction isolated from the fermentation broth of the fungus Curvularia verruculosa. This compound was originally reported as LL-Z1640-2, a zearalenone-like compound with modest inhibitory activity on growth and motility of the ciliated protozoan Tetrahymena pyriformis (Ellestad et al., 1978) and is now known as 5Z-7-oxo-zeaenol (Rawlins et al., 1999) . Because f152A1 is readily metabolized in biological fluids (plasma and liver microsomes) into pharmacologically inactive metabolites, the synthesis of analogs of f152A1 was undertaken to obtain metabolically stable compounds. Over 400 analogs were prepared, and E6201 emerged as a promising and stable candidate that retained the in vitro inhibitory effect on TNF␣ transcription of f152A1 and was selected for further pharmacological characterization.
In the present study, we characterized the in vitro activities of E6201, including its protein kinase inhibitory activities in cell-free and cell-based systems, inhibition of proinflammatory cytokine production from various immune cells, and inhibition of hyperproliferation of human keratinocytes. These results indicate that E6201 has potential for the treatment of psoriasis.
Materials and Methods
Reagents and Cells. Recombinant proteins MEKK1, MEK1, MKK4, MKK6, MBP-p38, GST-linker for activation of T cells, unactivated-MEK1, unactivated-MAPK/ERK2 (ERK2), unactivated-MKK6, unactivated-MKK4, unactivated-JNK and unactivated-p38␣ MAPK, anti-phospho-MBP, ZAP-70, purified PKC (mixture of ␣, ␤, and ␥) from rat brain, and Immobilon-P were purchased from Millipore Corporation (Billerica, MA). Lipopolysaccharide (LPS; Escherichia coli 0127:B08 or 011:B4), HEPES, betamethasone, and 1␣,25-dihydroxycholecalciferol were purchased from Sigma-Aldrich Co. (St. Louis, MO). The protein kinase C enzyme assay system, [␥- 32 P]ATP and [␥-33 P]ATP, ECL reagent, Ficoll-Paque PLUS, and ECL film were purchased from GE Healthcare (Chalfont St. Giles, Buckinghamshire, UK). RPMI 1640 medium and Hank's balanced salt solution were purchased from Invitrogen (Carlsbad, CA). Eu (K)-PY20, Eu (K)-PT66, XL665-SA, XL665-His 6 , and XL665-GST were purchased from Cisbio US (Bedford, MA). Phytohemagglutinin-P (PHA-P) was purchased from BD Biosciences (Franklin Lakes, NJ). Human recombinant IL-1␣, human recombinant TNF␣, and enzymelinked immunosorbent assay (ELISA) development kits for human IL-2, human TNF␣, human IL-6, and human IL-8 were purchased from Genzyme Techne (Minneapolis, MN). Anti-rabbit IgG (goat)-HRP-linked, anti-p44/42 MAPK antibody, anti-phospho-p44/42 MAPK antibody, anti-phospho-JNK antibody, and anti-phoshpo-p38 MAPK antibody were purchased from Cell Signaling Technology Inc. (Beverly, MA). Anti-phospho-IB␣ antibody, anti-p50 antibody, antip65 antibody, and anti-c-JUN antibody were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Human IL-1␤ ELISA kit and AlamarBlue reagent were purchased from BioSource International (Camarillo, CA). Phosphoimmune receptor tyrosine-based activation motif was purchased from Peptide Institute, Inc. (Minoh-shi, Osaka, Japan). Biotinylated-IB␣ peptide was synthesized in Toray Research Center (Nagoya-shi, Aichi, Japan). His-tagged kinase domain hepatocyte growth factor receptor, VEGFR2, FGFR1, and PDGFR␤, His-tagged full-length Syk, GST fused-JNK1, JNK2, JNK3, c-JUN, and IKK␤ were prepared in Eisai Tsukuba Laboratories (Tsukuba-shi, Ibaraki, Japan). The fermentation broth of the fungus C. verruculosa was obtained from Mercian Corporation (Iwata-shi, Shizuoka, Japan). f152A1, f152B1, f152C, and f152D2 were isolated from the culture broths at Eisai Tsukuba Laboratories. Cell-Based Assays with TNF␣-PLAP and ␤-Actin-PLAP Reporter Cells. THP-1-33 cells and B164 cells were maintained in RPMI 1640 medium containing 10% heat-inactivated endotoxin-free fetal bovine serum (FBS) and G418 (1 mg/ml). These cells were suspended at a density of 6.25 ϫ 10 4 cells/ml in RPMI 1640 medium containing 10% FBS. The cell suspension was seeded 160 l/well in 96-well plate and cultured in the presence or absence of test compounds for 30 min followed by stimulation with 100 ng/ml LPS (E. coli 0127:B08 or 011:B4). After 24 to 48 h, the culture supernatant was harvested, and alkaline phosphatase activity was measured as described previously (Goto et al., 1996) .
Protein Kinase Assays. MEK1, MKK4, MEKK1, ERK2, p38 MAPK, and ZAP-70 activities were measured as described by the manufacturer (Millipore Corporation).
JNKs activity assays were performed by mixing either GST-JNK1 (0.15 g) with GST-c-JUN (0.6 g), GST-JNK2 (0.22 g) with GSTc-JUN (0.4 g), or GST-JNK3 (0.035 g) with GST-c-JUN (0.6 g) in kinase buffer (25 mM HEPES, pH 7.5, 10 mM magnesium acetate, 1 mM ATP) containing [␥- 33 P]ATP (0.2 mCi/ml) in the presence or absence of E6201 in OptiPlate plates (PerkinElmer Inc., Waltham, MA). After 30 min at room temperature, reactions were stopped by the addition of a solution containing excess ATP (80 mM) and GSHscintillation proximity assay reagent. Plates were mixed for 30 min, centrifuged at 1000g for 5 min, and measured for radioactivity (Top Count NXT; PerkinElmer Inc.).
Syk autophosphorylation assay was performed by homogenous time-resolved fluorescence (HTRF). Full-length Syk (80 nM) was incubated with phosphoimmune receptor tyrosine-based activation motif (100 nM) in kinase buffer (25 mM HEPES, pH 7.5, 150 mM NaCl, 10 mM KCl, 0.5 mM EGTA, 5 mM NaF, 1 mM Na 3 VO 4 , 0.6 mM MgCl 2 , 0.6 mM MnCl 2 , 0.1% BSA) in the presence or absence of E6201. The reaction was initiated by addition of 10 l of ATP solution (0.56 M), incubated for 30 min at room temperature, and stopped by the addition of 10 l of EDTA (80 mM). The HTRF assay was performed by the addition of 20 l of HTRF solution [25 mM HEPES, pH 7.5, 425 ng/ml Eu (K)-PT66, 5 g/l XL665-His 6 , 1 M potassium fluoride, 0.1% BSA] to the reaction mixture, followed by a 20-h incubation at room temperature, and detection of fluorescence (Discovery HTRF microplate analyzer BD10011; PerkinElmer Inc.).
HTRF assays to measure VEGFR-2, FGFR1, c-Met, and EGFR kinase activity were initiated by mixing either VEGFR-2 (15 ng), FGFR1 (15 ng), c-Met (30 ng), or EGFR (23 ng) with biotinylatedpoly(GT) (250 ng) in kinase buffer (50 mM HEPES, pH 7.4, 20 mM MgCl 2 , 4 mM MnCl 2 , 0.5 mM Na 3 VO 4 ) in the presence or absence of E6201 upon addition of ATP solution (1 M). The reaction mixtures were incubated for 10 min at 30°C and terminated by the addition of EDTA (0.5 M). HTRF solution [20 mM HEPES, pH 7.0, 7.5 ng of Eu (K)-PY20, 250 ng of XL665-SA, 0.5 M potassium fluoride, 0.1% BSA] was added to the reaction mixture and processed as described above for the Syk assay.
PDGFR␤ kinase activity assay was performed using ELISA. Histagged PDGFR␤ (50 ng) was mixed with biotinylated-poly(GT) (250 ng) in kinase buffer (50 mM HEPES, pH 7.0, 20 mM MgCl 2 , 4 mM MnCl 2 , 0.5 mM Na 3 VO 4 ) in the presence or absence of E6201. The reaction was initiated by the addition of ATP solution (1 M), incubated for 30 min at 30°C, and terminated by the addition of EDTA (0.5 M). Reaction mixtures were transferred to 96-well streptavidincoated microtiter plates, washed, mixed with PY20-HRP solution, and incubated for 30 min. Kinase activity was determined by the addition of tetramethylbenzidine reagent, according to the manufacturer, and detection of absorbance at 450 nm in a microplate reader (SPECTRA MAX 250; Molecular Devices, Sunnyvale, CA).
For IKK␤ activity assays, GST-IKK␤ (20 ng) was mixed with biotinylated-IB␣ peptide (67.5 ng) in kinase buffer (25 mM HEPES, pH 7.5, 10 mM MgCl 2 , 2 mM MnCl 2 , 0.1% BSA) in the presence or absence of E6201. The reaction was initiated by the addition of ATP solution (50 M), incubated for 30 min at 30°C, and terminated by the addition of EDTA (10 mM). Reaction mixtures were transferred to 96-well streptavidin-coated microtiter plates, washed, mixed with HRP-conjugated anti-phospho-IB␣ antibody solution, and incubated for 60 min. The assay was processed as described above for the PDGFR␤ kinase activity assay. PKC activity was determined as described by the manufacturer (GE Healthcare).
Preparation of Cells for Primary Cell-Based Assays. Peripheral blood mononuclear cells (PBMCs) were separated from human blood as described previously (Goto et al., 1996) . PBMCs in RPMI 1640 medium containing 10% FBS were transferred to polystyrene dishes and incubated at 37°C in an atmosphere 5% CO 2 /95% air to remove adherent cells (mostly monocytes). After 1 h, the cultured supernatants containing nonadherent cells (most of them were lymphocytes) were collected, pooled, and centrifuged at 1500 rpm for 5 min at room temperature. The lymphocytes were resuspended with RPMI 1640 medium containing 10% FBS and 50 M 2-ME at an adequate density for subsequent experiments.
Human keratinocytes were suspended with KGM-2 medium containing KGM-2 SingleQuots [including 0.5 ml of human epidermal growth factor (EGF), 2 ml of bovine pituitary extract, 0.5 ml of insulin, 0.5 ml of transferrin, 0.5 ml of hydrocortisone, 0.5 ml of epinephrine, and 0.5 ml of GA-1000] at an adequate density for subsequent experiments.
Determination of Kinase Phosphorylation in Cell-Based Systems. Serum-starved (1 day) THP-1-33 cells were suspended at a density of 1.6 ϫ 10 5 cells/ml in RPMI 1640 medium containing 10% FBS and seeded at a volume of 5 ml/plastic dish. Cells were cultured in the presence or absence of E6201 for 30 min followed by stimulation with 100 ng/ml LPS for 5 min. Whole-cell extracts were prepared as described previously (Goto et al., 1996) .
Human lymphocytes were suspended at a density of 1 ϫ 10 6 cells/ml in RPMI 1640 medium containing 10% FBS and 50 M 2-ME and seeded at 7 ml/plastic dish. The cells were cultured in the presence or absence of E6201 for 30 min followed by stimulation with 10 l/ml PHA-P or 1 ng/ml TNF␣ for 5 min. Whole-cell extracts were prepared as described above.
Human keratinocytes were suspended at a density of 1.6 ϫ 10 4 cells/ml in KGM-2 medium containing KGM-2 SingleQuots and seeded at 2 ml/well in a six-well plate. After 4 days in culture, medium was replaced with fresh KGM-2 medium without KGM-2 SingleQuots. The next day, cells were cultured in the presence or absence of E6201 for 30 min followed by stimulation with 100 ng/ml EGF and 1 ng/ml TNF␣ for 20 min. Whole-cell extracts were prepared as described above. Western blot analysis was performed as described previously (Goto et al., 1996) with slight modifications. In brief, whole-cell extracts containing similar amounts of protein were analyzed by electrophoresis on 11 to 14% Tris-glycine-buffered polyacrylamide gradient gels in SDS. Proteins were transferred to membranes (Immobilon-P) with an electroblotter and probed with either rabbit anti-ERK1/2 antibody, antiphoshporylated-ERK1/2 antibody, antiphospho-JNK antibody, anti-phoshpo-p38 MAPK antibody, or antiphospho-IB␣ antibody plus HRP-conjugated anti-rabbit IgG antibody. Membranes were dried, incubated in ECL reagents, and exposed to film as indicated by the manufacturer.
Nuclear Factor Assays. THP-1-33 cells were suspended at a density of 5 ϫ 10 5 cells/ml in RPMI 1640 medium containing 10% FBS and seeded at 10 ml/25 cm 2 flask. The cells were cultured in the presence or absence of E6201 for 30 min followed by stimulation with 100 ng/ml LPS for 24 h. Nuclear extracts were prepared as described previously (Goto et al., 1996) .
Human lymphocytes were suspended at a density of 9 ϫ 10 5 cells/ml in RPMI 1640 medium containing 10% FBS and 50 M 2-ME and seeded at 7 ml/plastic dish. The cells were cultured in the presence or absence of E6201 for 30 min followed by stimulation with 1 ng/ml TNF␣ for 24 h. Jurkat cells were suspended at a density of 5 ϫ 10 5 cells/ml in RPMI 1640 medium containing 10% FBS and seeded at 7 ml/plastic dish. The cells were cultured in the presence or absence of E6201 for 30 min followed by stimulation with 20 g/ml PHA-P and 10 nM PMA for 6 h.
Human keratinocytes were suspended at a density of 1.2 ϫ 10 4 cells/ml in KGM-2 medium containing KGM-2 SingleQuots and seeded at 2 ml/well in a six-well plate. After 5 days in culture, the medium was replaced with fresh KGM-2 medium without KGM-2 SingleQuots, and the cells were cultured for an additional day. Cells were cultured in the presence or absence of E6201 for 30 min followed by stimulation with 2 ng/ml TNF␣ and 20 ng/ml EGF for 3 or 24 h. Gel-shift assays were performed according the method described previously (Goto et al., 1996) . In brief, nuclear extracts (2 l) containing similar amounts of protein were incubated with 32 P-labeled NF-B (containing GGGACTTTCC sequence) probe (77, 175 cpm/ng) and AP-1 (containing TGAGTCA sequence) probe (67,600 -81,200 cpm/ng) in binding buffer (10 mM Tris, pH 7.4, 40 mM NaCl, 10% glycerol, 1 mM EDTA, 1 mM dithiothreitol, 1% Nonidet P-40, 1% deoxycholate, 3 g/ml polydeoxyinosinic-deoxycytidylic acid). Reaction mixtures were incubated for 30 min at room temperature and subjected to gel electrophoresis to separate DNA/protein complexes from free DNA probes in a native 5% polyacrylamide gel. The gel was vacuum-dried, exposed to an imaging plate, and analyzed with the BAS2500 system. IL-2 Production from Human Lymphocytes. Human lymphocytes were suspended at a density of 3 ϫ 10 6 cells/ml in RPMI 1640 medium containing 10% FBS and 50 M 2-ME and seeded at 160 l/well in 96-well microtiter plates. Cells were preincubated with compounds for 30 min and stimulated by PHA-P for 2 days. The amount of IL-2 in the supernatant was determined by ELISA as described by the manufacturer of the kit.
Human Keratinocytes Proliferation Assay. Human keratinocytes were suspended at 1.5 ϫ 10 4 cells/ml in KGM-2 medium containing KGM-2 SingleQuots and seeded at 90 l/well in 96-well plates. The next day, compounds were added to the cells, and the cells were incubated for an additional 3 days. AlamarBlue reagent A Novel MEK1 and MEKK1 Inhibitor 487 at ASPET Journals on July 12, 2017 jpet.aspetjournals.org (10 l) was added to each well and further incubated for 2 h. The intensity of fluorescence in each well was measured using a multilabel counter (Wallac ARVO SX 1420; PerkinElmer Inc.).
IL-8 Production from Human Keratinocytes. Human keratinocytes were suspended in KGM-2 medium containing KGM-2 SingleQuots at a density of 5.3 ϫ 10 4 cells/ml and seeded at 100 l/wells in 96-well plates. The next day, cells were cultured in the presence of compound and 12.5 l of IL-1␣ (5 ng/ml) or TNF␣ (1 ng/ml) for 24 h. The amount of IL-8 in the supernatant was determined by the ELISA as described by the manufacturer of the kit.
Cytokine Production from PBMCs. Human PBMCs were suspended at 3.2 ϫ 10 5 cells/well and seeded at 160 l/well in a 96-well plate. Cells were cultured in the presence or absence of E6201 for 30 min followed by stimulation with 20 l of 100 ng/ml LPS for 24 h. Cytokine levels (TNF␣, IL-1␤, IL-6, and IL-8) in the supernatant were determined by ELISA as described by the manufacturer of the kit.
Results
Discovery of f152A1 as an Inhibitor of TNF␣ Transcription. Using LPS-activated TNF␣-PLAP reporter cells (THP-1-33 cells), strong inhibitory activity was found in a fraction originated from the fermentation broth of C. verruculosa. In the crude broth, 13 compounds containing a 14-member ring macrolide structure were isolated. Among these natural products, f152A1 was identified as the most potent inhibitor of TNF␣-PLAP reporter cells (IC 50 value: 11 Ϯ 1 nM) ( Fig. 1A; Table 1 ). f152A1 also decreased ␤-actin transcription, but its inhibitory activity was much weaker than TNF␣ transcription (Fig. 1A) . Chemical structures of representative natural products from the fermentation broth and those inhibitory activities on TNF␣-PLAP reporter assay are shown in Table 1 . f152B1, the trans-form of f152A1, displayed 30-fold weaker potency in the TNF␣-PLAP reporter assay, whereas reduction of the enone double bond (f152C) resulted in a compound with no inhibitory activity on TNF␣ transcription. f152D2, also known as hypothemycin, was slightly weaker than f152A1 in inhibiting TNF␣ transcription. In plasma and liver microsome preparations, f152A1 was rapidly isomerized to the trans-enone (f152B1) followed by reduction of the enone, thus abrogating its biological activity. Stabilization of the cis-enone was attained by the addition of a methyl group in the ␥-position (Table 1, . The (4S)-methyl analog of f152A1, ER-803064 (Table 1), was resistant to metabolism and inhibited TNF transcription with an IC 50 value of 136 Ϯ 8 nM (Table 1) .
Approximately 400 analogs were synthesized to increase compound potency, resulting in the identification of E6201, a promising analog that inhibited LPS-induced TNF␣ transcription with an IC 50 value of 50 Ϯ 14 nM (Table 1) , but did not suppress ␤-actin transcription at 3 M and only slightly at 10 M (Fig. 1B) .
Effects of E6201 on MAPK Activity. The effects of E6201 on the activities of several related members of the MAPK family were examined in cell-free systems. The results are summarized in Table 2 . E6201 inhibited MEK1-induced ERK2 phosphorylation with an IC 50 value of 5.2 nM, MKK4-induced JNK phosphorylation with an IC 50 value of 91 nM, and MKK6-induced p38␣ MAPK phosphorylation with an IC 50 value of 19 nM. E6201 also inhibited MEKK1-induced phosphorylation of MEK1, MKK4, and MKK6 with IC 50 values of 31, 522, and 65 nM, respectively. In contrast, E6201 had no effect on other MAPK family enzymes such as ERK2, JNKs, and p38 MAPK at 10 M. These data indicate that E6201 is an inhibitor of MEKK1 and MEK families but not the MAPK family.
Effect of E6201 on Activity of Tyrosine Kinases, IKK␤, and Protein Kinase C. E6201 inhibited the receptor tyrosine kinases VEGFR2, PDGFR␤, hepatocyte growth factor receptor, and EGFR with IC 50 values of 350, 860, 1100, and 5400 nM, respectively, as well as the nonreceptor tyrosine kinase Syk with an IC 50 value of 460 nM (Table 3) . E6201 did not inhibit ZAP-70 or IKK␤ at 10 M or PKC activity at 100 M.
Effect of E6201 on the Phosphorylation of MAPKs in Various Cells. To determine whether E6201 inhibits MEK1 activity in cells, we examined the phosphorylation state of ERK1/2 in various cell systems. In serum-starved THP-1-33 cells, ERK2 phosphorylation was elevated by LPS treatment, whereas ERK1 remained constitutively phosphorylated compared with untreated control. E6201 dose-dependently inhibited LPS-induced phosphorylation of ERK2 and constitutively activated-ERK1 at concentrations of up to 1 M. There were very modest effects on total ERK1 and 2 protein levels, which may contribute to an observed treatment effect on phosphorylated ERKs in THP-1-33 cells ( Fig. 2A) . We also examined the effect of E6201 on human lymphocytes and keratinocytes, because the activation of these cells seems to play a role in the pathogenesis of psoriasis. E6201 at 1 M also completely inhibited PHA-P-induced and EGF/TNF␣-stimulated ERK1/2 phosphorylation in human lymphocytes 2B ) and human keratinocytes (Fig. 2C) , respectively. Through the course of these experiments, there were no effects of E6201 on total ERK1 and 2 protein levels in all cells. These results indicated that E6201 inhibited ERK1/ ERK2 phosphorylation in various cell systems. To determine whether the inhibitory effects of E6201 on MEKK1 are observed in cell-based systems, we examined the phosphorylation of downstream kinases of MEKK1 in TNF␣-stimulated human lymphocytes. In human lymphocytes stimulated with TNF␣, phosphorylation of ERK1/2, JNK, p38 MAPK, and IB␣ was observed and E6201 inhibited the phosphorylation of all four proteins in a dose-dependent manner (Fig. 3) . The concentrations of E6201 required to inhibit phosphorylation vary for each substrate. This is consistent with the different potencies observed for E6201 inhibition of different kinases (Table 2 ) and possibly for differential cell compartmentalization of each individual protein kinase.
Effect of E6201 on NF-B and AP-1 Activation. We examined the effect of E6201 on the activation of NF-B and AP-1 by gel-shift assay in four different cell types. Both NF-B and AP-1 were detected in the nuclei of THP-1-33 cells at 24 h after stimulation by LPS, and E6201 inhibited the activation of NF-B and AP-1 in a dose-dependent manner (Fig. 4A) . We next examined the effect of E6201 on human lymphocytes and keratinocytes. Activation of NF-B and AP-1 was observed in PHA-stimulated human lymphocytes (Fig. 4B) and PHA/PMA-costimulated Jurkat cells (Fig. 4C) . E6201 inhibited activation of NF-B and AP-1 in both cell types in a dose-dependent manner. In human keratinocytes, activation of NF-B was observed at 3 h but not 1 day after costimulation with TNF␣ and EGF, whereas activation of AP-1 occurred at 24 h but not at 3 h after costimulation. E6201 inhibited the activation of NF-B and AP-1 in human keratinocytes in a dose-dependent manner (Fig. 4D) . The inhibitory concentration and inhibitory level of E6201 on kinases (Fig. 3 ) and transcription factors (Fig. 4) varied in each cell because of individual cell preparations. Taken together, these data indicate E6201 inhibits the activation of both NF-B and AP-1 in human THP-1-33 cells, Jurkat, lymphocytes, and keratinocytes.
Effect of E6201 on IL-2 Production from Human Lymphocytes. We examined the effect of E6201 on IL-2 production from lymphocytes and discovered that the compound inhibited IL-2 production 48 h after stimulation with the T-cell mitogen PHA-P, with an IC 50 value of 18 nM (Fig.  5) . Betamethasone and 1␣,25-dihydroxycholecalciferol also inhibited the IL-2 production with IC 50 values of 1.7 and 6.3 nM, respectively. These results indicate that E6201 inhibits lymphocyte activation, consistent with effects observed with steroids and vitamin D 3 analogs.
Effect of E6201 on Human Keratinocytes. We investigated the effect of E6201 on the proliferation of human keratinocytes and discovered that the compound inhibited the proliferation of EGF-stimulated human keratinocytes with an IC 50 value of 160 nM (Fig. 6 ). Betamethasone (100 -3000 nM) and 1␣,25-dihydroxycholecalciferol (10 -100 nM) had modest inhibitory effects on cell proliferation, but the dose responses were unclear in this assay.
E6201 suppressed IL-8 production in human keratinocytes 24 h after stimulation with IL-1␣ or TNF␣, with IC 50 values of 60 (Fig. 7A ) and 30 nM (Fig. 7B ), respectively. E6201 had no appreciable effect on cell viability at 1000 nM. These results indicate that E6201 inhibits IL-8 production and proliferation of activated keratinocytes.
Effect of E6201 on Cytokine Production from Human PBMCs. LL-Z-1640-2 (5Z-7-oxo-zeaenol; same natural product as f152A1) and its analogs are known as inhibitors of inflammatory cytokine production, such as TNF␣, IL-1␤, and IL-6. Here, the effects of E6201 on cytokine production were evaluated in LPS-stimulated human PBMCs. As shown in Table 4 , E6201 inhibited TNF␣, IL-1␤, IL-6, and IL-8 production from human PBMCs with IC 50 values of 20, 16, 52, and 53 nM, respectively. Cytotoxicity was determined simultaneously by the addition of AlamarBlue reagent, and it was confirmed that E6201 did not show any cytotoxicity even at 1 M in this assay (data not shown). Betamethasone also inhibited all cytokines tested, and the potency was stronger than E6201. 1␣,25-dihydroxycholecalciferol inhibited TNF␣ production, with an IC 50 value of 3.4 nM, but did not inhibit IL-6 and IL-8 production. These results indicate that E6201 inhibits production of proinflammatory cytokines from human PBMCs, an effect also observed with betamethasone.
Discussion
E6201 is a fully synthetic analog of the natural product f152A1 that was isolated from the fermentation broth of C. verruculosa. f152A1 was reported previously as LL-Z1640-2 (Ellestad et al., 1978) or 5Z-7-oxo-zeaenol (Rawlins et al., 1999) . The biological activities of f152A1 and its derivatives have been reported: inhibition of growth and motility of ciliated protozoan T. pyriformis (Ellestad et al., 1978) ; inhibition of IL-1␤ release from human monocytes (Kastelic et al., at ASPET Journals on July 12, 2017 jpet.aspetjournals.org Downloaded from 1996); inhibition of endotoxin-induced TNF␣ production from U937 cells (Rawlins et al., 1999) ; inhibition of T-cell activation (Camacho et al., 1999) , Ras signaling (Tanaka et al., 1999) , JNK/p38 pathways (Takehana et al., 1999) , and TAK1 activation (Ninomiya-Tsuji et al., 2003); and inhibition of MEK (Zhao et al., 1999; Ohori et al., 2007) . The number of reported in vivo effects of f152A1 and related compounds is more limited. For example, radicicol analog A inhibits LPSinduced pyrexia with an oral ED 50 of 0.3 mg/kg and carrageenan-induced paw edema in a similar dose-range (Elford et al., 1996) , and topically administered 5Z-7-oxozeaenol (1 mg/ml) reduces picryl chloride-induced ear swelling (Ninomiya-Tsuji et al., 2003) .
Our previous results indicate that f152A1 is rapidly metabolized in biological fluids by epimerization of the ␣,␤-enone double bond followed by reduction of the enone double bond resulting in poor in vivo activity of f152A1 (data not shown). Given the poor stability of the enone, it was hypothesized that modification of this moiety results in a more stable compound with improved pharmacological properties compared with f152A1. ␥-Methylation of the enone in f152A1 led to the discovery of ER-803064 with improved plasma stability and in vivo efficacy in mice challenged with LPS (J. Wang, manuscript in preparation). Approximately 400 analogs of f152A1 were synthesized, leading to the identification of the ethyl-amide analog of ER-803064, E6201, as the most active analog in vivo (K. Muramoto, manuscript in preparation).
In the present study, we describe that E6201 inhibits MEK1 activity and the phosphorylation of ERK1/2, a substrate of MEK1, in several different cell types. E6201 also inhibits the activity of other MEK family members, MKK4 Although E6201 did not inhibit ERK2, JNK, and p38 MAPK activity in cell-free systems, it showed inhibition of phosphorylation of these kinases via inhibition of upstream kinases. These results strongly suggest that E6201 can inhibit signaling through MEKK1 and MEKs pathways in various cellbased systems.
MEK1 activation has been shown to lead to AP-1 activation via signaling through ERK proteins (Karin, 1995) . Activated AP-1 is a transcription factor that plays a significant role in IL-2 (Jain et al., 1992) and IL-8 (Yasumoto et al., 1992) transcription, similar to activated NF-B (Shibuya and Taniguchi, 1989) . We observed that E6201 inhibits AP-1 activation in several different cells, suggesting that the inhibitory effects of E6201 on IL-2 production from PHA-stimulated A, THP-1-33 cells were pretreated with or without E6201 (0.1-3 M) for 30 min followed by stimulation with LPS (100 ng/ml) for 1 day. B, human lymphocytes were pretreated with or without E6201 (0.1-3 M) for 30 min and stimulated with PHA-P (10 l/ml) for 5 min. C, Jurkat cells were pretreated with or without E6201 (0.03-1 M) for 30 min followed by stimulation with PHA-P (10 l/ml) and PMA (20 nM) for 6 h. D, human keratinocytes were pretreated with or without E6201 (0.1-3 M) for 30 min and stimulated with TNF␣ (1 ng/ml) for 3 h (for the detection of NF-B activation) or 1 day (for the detection of AP-1 activation). Nuclear extracts were prepared and incubated with NF-B or AP-1 double-stranded oligonucleotide.
The radioactivity of specific NF-B/DNA or AP-1/DNA complex was calculated with the BAS2500 system.
human lymphocytes and IL-8 production from cytokine-stimulated human keratinocytes are due to inhibition of AP-1 activation as a result of MEK1 inhibition. Furthermore, activation of AP-1 leads to the enhancement of proliferation of various cell types (Angel and Karin, 1991) . MEK1, which activates AP-1, plays an important role in epidermal hyperproliferation and skin inflammation (Hobbs et al., 2004) . Because E6201 attenuated AP-1 activation in human keratinocytes costimulated with EGF and TNF␣, the inhibitory effect of E6201 on proliferation of human keratinocytes may be mediated by MEK1 inhibition. Inhibition of IL-2 production from lymphocytes and proliferation of keratinocytes were observed with E6201, as well as agents such as betamethasone and 1␣,25-dihydroxycholecalciferol that are currently used as topical therapeutics for psoriasis. Betamethasone suppresses AP-1 activity through the glucocorticoid receptor (Pearce and Yamamoto, 1993) , and 1␣,25-dihydroxycholecalciferol inhibits nuclear factor of activated T cell (NFAT)p/AP-1 complex formation through the vitamin D 3 receptor (Alroy et al., 1995) . Tazarotene, a retinoic acid derivative used for psoriasis treatment, is known to inhibit AP-1 activity by the interaction of retinoidreceptor complex (Chandraratna, 1996) . These reports suggest that AP-1 inhibition may be beneficial for the treatment of psoriasis.
E6201 inhibited TNF␣, IL-1␤, IL-6, and IL-8 production from LPS-stimulated human PBMCs. Previous studies have shown that transcription of these cytokines is regulated by NF-B (Baeuerle, 1991) . Indeed, E6201 attenuated the activation of NF-B in the human monocytic cell line THP-1-33, results that are consistent with the hypothesis that inhibition of NF-B activation is one of the mechanisms by which E6201 inhibits proinflammatory cytokine production.
NF-B activation is mediated by IKK␤ through the phosphorylation of IB␣, which results in the removal of IBa for the translocation of NF-B to the nucleus (Woronicz et al., 1997) . Although E6201 did not inhibit phosphorylation of IB␣ by IKK␤ in a cell-free system, E6201 prevented TNF␣-stimulated IKK␤-induced phosphorylation of IB␣ in human lymphocytes. Moreover, E6201 inhibited phosphorylation of IB␣ in signalsomes that were immunoprecipitated with anti-IKK␥ antibody from TNF␣-stimulated human endothelial cells (data not shown). The signalsome that immunoprecipitated with anti-IKK␥ antibodies is a large complex (500 -700 kDa) containing IKK␣, ␤, ␥, and MEKK1 (Mercurio et al., 1997) . MEKK1 is believed to be a molecular target of E6201 along with other kinases that have been reported to affect the NF-B pathway. For example, TAK1 (Sakurai et al., 1999) and MEKK3 (Yang et al., 2001 ) phosphorylate IKK␤, and f152A1 (5Z-7-oxozeaenol) has been reported to inhibit TAK1 (Ninomiya-Tsuji et al., 2003) .
Inhibitory effects on proinflammatory cytokines were observed with betamethasone, although the inhibitory mechanisms are quite different from E6201. In addition, 1␣,25-dihydroxycholecalciferol showed inhibition of TNF␣ and IL-1␤ production, but not IL-6 and IL-8 production. E6201 suppressed IL-8 production from human keratinocytes stimulated with IL-1␣ or TNF␣. These cytokines are detected in psoriatic plaques and play important roles in inflammatory processes (Schröder et al., 1992 , Nickoloff et al., 2007 . Biological therapeutics targeting TNF␣ can be especially effective against severe plaque psoriasis (Chaudhari et al., 2001; Leonardi et al., 2003) . The inhibitory effects of E6201 on the production of these proinflammatory cytokines, as well as its effects on proliferation of keratinocytes, may contribute to efficacy of E6201 for the treatment of psoriasis.
It has been reported that MEK1 activation regulates production of TNF␣ (van der Bruggen et al., 1999) and IL-1␤ (Means et al., 2000) , whereas p38 MAPK plays an important role in the production of IL-6 (Lee et al., 1990 ) and IL-8 (Fietta et al., 2002) . The upstream kinases of MEK1 and p38 MAPK are MEKK1 and MKK6, respectively. Because E6201 attenuated the activity of MEKK1 and MKK6, the inhibitory effects of E6201 on these kinases, together with inhibition of NF-B activation as noted above, may contribute to inhibition of production of proinflammatory cytokines.
The effects of E6201 on the MAPKs cascade are summarized in Fig. 8 . E6201 strongly inhibits MEK1, ERK1/2, and AP-1 activation, which is believed to lead to the inhibition of cell proliferation. E6201 inhibits phosphorylation of MEKs by MEKK1, suppressing not only MEK1 but also MKK4 and MKK6 activity. In addition, inhibition of MEKK1 by E6201 may also lead to the reduction of IKK␤ activity. The inhibitory effects of E6201 on one or more of MKK4, MKK6, and IKK␤ may contribute to the inhibition of the downstream events, including the production of proinflammatory cytokines. Suppression of proinflammatory cytokines may be beneficial for the treatment of various chronic inflammatory conditions. The salient property of E6201, in addition to its potent anti-inflammatory profile, is its antiproliferative effect. This combination of anti-inflammatory and antiproliferative properties should be ideal for the treatment of psoriasis. Topical application of E6201 showed excellent efficacy in different models of dermatitis in mice: croton-oil induced inflammation, delayed-type hypersensitivity reaction, and phorbol ester-induced keratinocyte proliferation model (K. Muramoto, manuscript in preparation) . Although the precise mechanisms of psoriasis pathogenesis are unclear, it is well understood that initiation and formation of psoriasis in clinical state are driven by the immune system, including activated T cells that trigger inflammation in epidermis and hyperproliferation of keratinocytes. E6201 inhibited both PHA-stimulated IL-2 production from lymphocytes and proliferation of EGF-stimulated human keratinocytes. Furthermore, E6201 suppressed production of proinflammatory cytokines, including TNF␣ from PBMCs. From these in vitro results, E6201, a new synthetic analog of f152A1 and an inhibitor of MEKK1 and MEK1, may be useful for the treatment of psoriasis without adverse systemic effects of hormone therapy. 
